|drug3669||allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC) Wiki||1.00|
|drug3153||Standard of care therapy Wiki||1.00|
There is one clinical trial.
This clinical trial is set out to evaluate the safety and efficacy of allogeneic human dental pulp mesenchymal stem cells in the treatment of severe pneumonia caused by COVID-19; to explore the effects of human dental pulp mesenchymal stem cells in the treatment of severe pneumonia of COVID-19 in terms of reducing mortality and improving clinical prognosis; and to discover a new therapeutic strategy for COVID-19 using allogeneic human dental pulp mesenchymal stem cells.
Description: Time to Clinical ImprovementMeasure: TTCI Time: 1-28 days
Description: Lung Lesion by CTMeasure: Lung lesion Time: 1-28 days
Description: Th1 cytokines: IL-1β, IL- 2, TNF-a, ITN-γ; Th2 cytokines: IL- 4, IL- 6, IL- 10; Immunoglobulins: IgA, IgG, IgM, and total IgE; Lymphocyte counts: CD3+, CD4+, CD8+, CD16+,CD19+, CD56+.Measure: Immune function Time: 1-28 days
Description: Time of SARS-CoV-2 test turns negativeMeasure: Time of SARS-CoV-2 clearance Time: 1-28 days
Description: Blood cell count and classificationMeasure: Blood test Time: 1-28 days
Description: Pulse oximetryMeasure: SPO2 Time: 1-28 days
Description: Respiratory rateMeasure: RR Time: 1-28 days
Description: Body temperatureMeasure: Body temperature Time: 1-28 days
Description: Number of the included patients with hDPSCs-related adverse events, e.g. liver or kidney function failureMeasure: Side effects in the treatment group Time: 1-28 days
Description: C-reactive protein in microgram per litreMeasure: C-reactive protein (mg/L) Time: 1-28 days
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports